Researchers identify potential biomarkers of age-related macular degeneration

September 12, 2017
Picture of the back of the eye showing intermediate age-related macular degeneration. Credit: National Eye Institute

Patients with any stage of age-related macular degeneration (AMD) carry signs of the disease in their blood that may be found through special laboratory tests, according to a new study led by AMD researchers based at Massachusetts Eye and Ear. The study, published online today in Ophthalmology, describes a new technique known as "metabolomics," which can identify blood profiles associated with AMD—the leading cause of adult blindness in developed countries—and its level of severity. These potential lipid biomarkers in human blood plasma may lead to earlier diagnosis, better prognostic information and more precise treatment of patients with AMD, as well as potential new targets for AMD treatment.

"With metabolomics, we can identify profiles associated with AMD and its severity through laboratory testing," said co-senior author Joan W. Miller, M.D., Chief of Ophthalmology at Mass. Eye and Ear and Massachusetts General Hospital, and Chair of Ophthalmology and the David Glendenning Cogan Professor of Ophthalmology at Harvard Medical School. "Because the signs and symptoms of early stage AMD are very subtle, with visual symptoms only becoming apparent at more advanced stages of the disease, identification of biomarkers in human blood plasma may allow us to better understand the early to intermediate stages of AMD so we may intervene sooner, and ultimately provide better care."

AMD is the leading cause of blindness in people over 50 in developed countries, and its prevalence is expected to increase along with the global aging of the population. While AMD has recognized genetic and lifestyle risk factors, including diet and smoking status, the field currently lacks reliable measures to identify patients who may be at risk of developing AMD, including those who may progress to the advanced, blinding forms of the disease.

"The study utilized a technique known as metabolomics, or the study of the tiny particles called metabolites, in our body that reflect our genes and environment," explained first author Ines Lains, M.D., a research fellow at Mass. Eye and Ear. "The metabolome—the set of metabolites present in an individual—is thought to closely represent the true functional state of complex diseases. This is why we used it to test 90 blood samples obtained from study participants with all stages of AMD (30 with early-stage disease, 30 with intermediate-stage and 30 with late-stage) and 30 samples from patients without AMD." The metabolomics data analysis was performed in collaboration with Dr. Lasky-Su and colleagues at the Channing Division of Network Medicine of Brigham and Women's Hospital.

Their approach revealed 87 metabolites, or small molecules in the blood, that were significantly different between subjects with AMD and those without. Furthermore, the team noted varying characteristics between the blood profiles of each stage of disease. This information has the potential to improve earlier diagnoses for AMD patients, and ultimately, may lead to more treatment options, as well as personalized treatment, for earlier stages of the disease.

Of the 87 molecules identified through metabolomics in the study to be associated with AMD, most belonged to the lipid pathway. In fact, six of the seven most significant metabolites identified in the study were lipids. Previous research has suggested that lipids may be involved in the development of AMD, although the exact role of lipids in the disease process remains unclear. The results from this study support this suggestion, as well as indicate that metabolomics profiling may provide novel insights into relationship between lipids and AMD.

"We believe this work will help launch the era of personalized medicine in treatment of AMD," said co-senior author Deeba Husain, M.D., a retina specialist at Mass. Eye and Ear and Associate Professor of Ophthalmology and co-director of the AMD Center of Excellence at Harvard Medical School. "Our work gives us a novel biomarker for early diagnosis, and it gives us clues to differentiate the progressers from non-progressors. This research also gives us insight into important role of lipids in AMD, which will provide novel targets for treatment in the early stage of disease, thus preserving vision in AMD."

Explore further: Blood test for early detection of pancreatic cancer headed to clinic

More information: Inês Laíns et al, Human Plasma Metabolomics Study across All Stages of Age-Related Macular Degeneration Identifies Potential Lipid Biomarkers, Ophthalmology (2017). DOI: 10.1016/j.ophtha.2017.08.008

Related Stories

Blood test for early detection of pancreatic cancer headed to clinic

July 12, 2017
A newly identified biomarker panel could pave the way to earlier detection and better treatment for pancreatic cancer, according to new research from the Perelman School of Medicine at University of Pennsylvania. Currently ...

Diagnostic biomarkers in saliva show promise in recognizing early Alzheimer's disease

May 18, 2017
Your spit may hold a clue to future brain health. Investigators at the Beaumont Research Institute, part of Beaumont Health in Michigan, are hopeful that their study involving small molecules in saliva will help identify ...

Metabolic markers accurately diagnose typhoid fever

May 9, 2017
Researchers have identified a metabolite 'signature' that can accurately distinguish typhoid from other fever-inducing tropical diseases using patient blood samples.

New approach could lead to blood test to diagnose Alzheimer's in earliest stage

May 29, 2013
Blood offers promise as a way to detect Alzheimer's disease at its earliest onset, Mayo Clinic researchers say. They envision a test that would detect distinct metabolic signatures in blood plasma that are synonymous with ...

Researchers identify key compounds to resolve abnormal vascular growth in AMD

August 21, 2017
A compound of specific bioactive products from a major family of enzymes reduced the severity of age-related macular degeneration (AMD) in a preclinical model, according to a new study led by Massachusetts Eye and Ear researchers. ...

Recommended for you

Scientists engineer drug delivery device that treats glaucoma directly inside the eye

November 23, 2017
Glaucoma, which affects over 60 million people worldwide, can seem easy to treat: medicated eye drops can be used to ease the buildup of fluid in the eye that underlies the condition. If glaucoma is caught early, eye drops ...

Research reveals biological mechanism of a leading cause of childhood blindness

November 16, 2017
Scientists at the Virginia Tech Carilion Research Institute (VTCRI) have revealed the pathology of cells and structures stricken by optic nerve hypoplasia, a leading cause of childhood blindness in developed nations.

Genetic treatment for blindness may soon be reality

November 11, 2017
Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting ...

Study finds donor corneas can be safely preserved for longer period

November 10, 2017
Results from a large, national clinical trial show that corneal donor tissue can be safely stored for 11 days without negatively impacting the success of transplantation surgery to restore vision in people with diseases of ...

Exploring the genetics of glaucoma and retinal development

November 10, 2017
Guillermo Oliver, PhD, the Thomas D. Spies Professor of Lymphatic Metabolism, recently published two studies related to the eye, one on retinal formation and the other on the genetics behind glaucoma.

Scientists discover potential treatment to stop glaucoma in its tracks

November 6, 2017
Vision scientists at the University of California, Berkeley, and the University of Toronto have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.